about
Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based dataThe PHD3 domain of MLL acts as a CYP33-regulated switch between MLL-mediated activation and repression .Chromatin conformation signatures of cellular differentiationChromatin modifications as therapeutic targets in MLL-rearranged leukemia.Childhood B-acute lymphoblastic leukemia: a genetic update.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations.The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemiasAF10 plays a key role in the survival of uncommitted hematopoietic cells.Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia.Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangementsMLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: a Children's Oncology Group (COG) study.Novel Cryptic Rearrangements in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Involving the MLL Gene.ALL-1/MLL1, a homologue of Drosophila TRITHORAX, modifies chromatin and is directly involved in infant acute leukaemia.Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondOutcomes after induction failure in childhood acute lymphoblastic leukemia.The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.Distinctive genotypes in infants with T-cell acute lymphoblastic leukaemia.H3K79 methylation profiles define murine and human MLL-AF4 leukemias.Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents.Unrelated hematopoietic stem cell transplantation for children with acute leukemia: experience at a single institution.Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia.Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia.Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia.Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals.Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors.Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution.Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy.A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy.MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.PARPi potentiates with current conventional therapy in MLL leukemia.Acute myeloid leukemia with KMT2A-SEPT5 translocation: A case report and review of the literature.
P2860
Q24798793-73877A02-28A2-452D-8741-00F02C95DF2DQ27663805-3A87F8A6-4EE3-4563-A129-B405307004EBQ33431476-4DECA701-368A-49E9-9DB9-F7B94E070A30Q33666543-12C63826-80D0-4E53-B639-676939F41EB4Q33777616-5F94E6B6-A744-4DF6-B316-62A4EF396F7FQ34031153-705E48A1-9C0A-4C71-B88D-5C95D7C62261Q34210998-4D687B90-67FE-4364-8267-0E907F4060ACQ34465221-ED87AAC3-6BA5-4B1C-9187-E7AD67266A74Q34532074-82A0A116-F14E-4692-815C-1565C3CA2C48Q34845478-52792E34-1DBD-49A9-9274-494077F510CBQ35101250-C6723E03-7B87-465C-AC8F-1F979AF6AE3DQ35147070-0B7D2937-5E3E-40B0-9C64-0071EFB1D8D7Q35523692-F970F05F-8A89-49CD-87B8-4E9B55D8E0ACQ35538663-3EEC350C-8A30-4044-9425-127C02CE0033Q35670201-BA046348-C4E5-46DC-8536-7B298563A30AQ35847465-3B52B840-F9DD-448D-94AB-7331F9A5349BQ35967446-C20F5FC1-347A-4AA7-9F66-2ACF6DAE3F3CQ36029619-6BC3FBF6-7844-444F-80E1-7299D749A751Q36250669-D5E27AEB-CD67-4626-85A8-8423419B624AQ36532587-6216F698-1038-459E-8AA1-93354BB3E991Q36991857-D1CCB41B-3755-4079-B364-59DF2ED3808EQ37234107-DEA95A0D-C09A-42B0-8849-C80D58544E26Q37260555-550858BC-06BB-4C59-8A24-D6B5B348DB9BQ37364550-D4817244-843A-47FB-B6A7-11475C417C36Q37515885-2A33ACD5-B58B-4BB6-A4B1-1D9DE64C1C6AQ37901485-46FAD8C6-9A43-4288-82E1-E6D882FD88FAQ39253931-C7A7AEB9-0B86-43C8-94D5-08B3FFCAD1B9Q39585715-472F7D6C-5DC7-4AB6-BF8F-B95C821E10AEQ39997748-10E6D4E2-7471-4D0B-B317-019870B4D174Q41133881-5A1B5B1B-9FD7-4509-89B2-51F75D8DE3EFQ41432593-A3B21E95-34FA-4A91-AC51-E9DE290379ABQ42193771-B8D24435-F4EE-443F-85CC-E8113C01AC2FQ42314704-15B9712E-A874-4DED-8ACD-874C1929A4DEQ47833710-371AC882-22C2-4685-B0E3-B4C3C17E1CC7Q49835968-9BFDFB49-0565-4477-8456-1B63319AAD70
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biological and therapeutic aspects of infant leukemia.
@ast
Biological and therapeutic aspects of infant leukemia.
@en
type
label
Biological and therapeutic aspects of infant leukemia.
@ast
Biological and therapeutic aspects of infant leukemia.
@en
prefLabel
Biological and therapeutic aspects of infant leukemia.
@ast
Biological and therapeutic aspects of infant leukemia.
@en
P2093
P1433
P1476
Biological and therapeutic aspects of infant leukemia.
@en
P2093
P407
P577
2000-07-01T00:00:00Z